Objectives: Infection with specific pathogens may lead to increased adiposity: a specific adiposity-promoting effect of Ad36 human adenovirus, without the involvement of neurological mechanisms, was reported. The aim of this study is to investigate whether non-diabetic patients with earlier Ad36 infection show greater degrees of overweight obesity, of Insulin Resistance (IR), assessed by homoeostasis-model assessment (HOMA), and/or of other related factors. Moreover, the relationship, if any, among these factors and an earlier Ad36 infection, and the hypothesis of a mechanism involving IR are investigated. Subjects: Ad36 seropositivity is assessed in 68 obese and 135 non-obese subjects, along with body composition, HOMA and laboratory investigations. Results: Age, body mass index (BMI), waist-hip ratio, blood pressure, insulin, HOMA and triglycerides are significantly greater in the Ad36 seropositive group. Ad36 seropositivity, along with HOMA and total cholesterol, explains BMI variance. No Ad36 seropositivity effect to HOMA could be envisaged by the same statistical model. Conclusion: A significant association of Ad36 seropositivity with obesity and with essential hypertension in human beings is suggested by our study; this association is mostly significant in women. Our results do not support that any Ad36 adipogenic adenovirus effect is operating in human obesity through an insulin-resistance-related mechanism. Ad36 seropositive status could also be a hallmark of a clinical-metabolic profile possibly preceding obesity and diabetes in non-obese patients.
Introduction
Infections may lead to increased adiposity: this fact has engendered several attractive, but quite conjectural hypotheses, with evidence attained mostly from animal studies. [1] [2] [3] A higher prevalence of human adenovirus Ad36 antibodies seropositivity is present in obese people compared with nonobese. 4 The nearly simultaneous increase in the prevalence of obesity in most countries of the world can be explained by changes in food intake and exercise alone, but the possibility that other environmental and infectious factors could have contributed is suggested. 5 Ad36 increases adiposity in chickens, mice, and non-human primates and paradoxically reduces serum cholesterol and triglycerides in animal models. Ad37 is another human adenovirus that increases adiposity and reduces serum triglycerides in an animal model, but increases serum cholesterol; also Human Adenovirus-5 has been shown to produce obesity in mice without any neurological involvement. 6 The increase in obesity in recent years has occurred among all socioeconomic groups: this provides support for a broad set of social and environmental explanations. 7, 8 Conceivably, increases in food availability, food salience, and the sophistication of modern marketing can make an important contribution to the obesity epidemic. Nonetheless, some mechanism seems to be operating below the level of individual awareness and beyond individual control. [9] [10] [11] Insulin resistance (IR) is involved and insulin-sensitivity improvement is maintained in obese patients for 2-3 years after dietary weight loss if weight is not regained. 12, 13 The observation of a paradoxical increase of insulin sensitivity in animals infected by Ad36 14 is intriguing and envisages the possibility that a better glycemic control in Ad36-infected subjects could be achieved. The mechanisms involved appear to lead to expansion of adipose tissue and increase of glucose uptake in skeletal muscle and adipose tissue, which collectively might lead to better glycemic control in vivo. 15 Increased body weight (BW) is a relevant factor for many diseases, including essential hypertension, whose relationship with obesity is indicated by the increase of some dimensions, and especially body mass index (BMI), waisthip ratio (WHR), and relative body composition, which, assessed by bio-impedance assessment (BIA), can provide detailed information on body compartments. 13 Little information on the relationship, if any, of adenoviruses seropositivity with circulating insulin, IR, and body composition is presently available. Central obesity has been reported to correlate strongly with IR 16 and is considered as a hallmark shared by obesity, hypertension, and diabetes. 17 The aim of this study is to investigate whether non-diabetic patients with earlier Ad36 infection show greater degrees of overweight obesity (OB), of IR, assessed by HOMA, 18 and/or of other related factors. Moreover, the relationship, if any, among these factors and an earlier Ad36 infection, and the hypothesis of a mechanism involving IR are investigated.
Patients and methods
A total of 203 consecutive patients were included in this study. They were referred to the Internal Medicine Clinic and Day hospital for clinical-nutritional assessment and counselling and followed thereafter for 6 months. Each patient gave informed consent to this study addressed to investigate a possible infectious component in the pathogenesis of obesity. Obese (n ¼ 68) and non-obese (n ¼ 135) patients were eligible according to the following exclusion criteria.
Patients with acute and/or chronic disease, history of alcohol abuse (exceeding 20 g per day), earlier HBV and/or HCV infections, other chronic infectious disease, congestive heart failure, renal insufficiency (estimated Glomerular Filtration Rate (eGFR) below 60 ml min -1 per 1.73 m 2 and/or detection of proteinuria), oncological disease, thyroid disease, polycistic ovary and steroid use were preliminarily excluded.
Patients with any history of diabetes mellitus, established by a fasting glucose level X126 mg per 100 ml or HbA1cX6.5%, or those under treatment for other disease, apart from wellcontrolled arterial hypertension, were excluded from this study.
Routine laboratory tests included virus hepatitis (HAV, HBV and HCV) and cancer markers (AFP, CEA, Ca125, Ca15-3), fT3, fT4, TSH, PTH, AST, ALT, g-glutamyl transpeptidase, ferritin, total protein and albumin. Arterial hypertension, defined as 4140 mm Hg of systolic and 490 mm Hg of diastolic blood pressure, was not an exclusion criterion provided that maintenance of adequately stable normal blood pressure was achieved. Throughout the study, only very few anti-hypertensive drugs were allowed, that is losartan (all hypertensive patients on treatment), atenolol and chlortalidone (individual patients not fully responding to losartan alone); no other anti-hypertensive drug and no psychotropic drug were allowed. BIA of body composition was performed by a singlefrequency BIA device 50 kHz and 800 mA (model BIA 101 RJL; Akern, Firenze, Italy) according to the standard tetrapolar technique; electrodes were placed on the feet, ankles, hands and wrists. The body composition was calculated from BIA measurements (resistance and reactance) and anthropometric variables (BW and H), using the software provided by Akern/ RJL Systems. This predictive model allows for calculation of total body water, body fat mass (BIA-FM) and fat-free mass (BIA-FFM), body cell mass and extracellular water; all measurements are expressed in kilograms and in relative percentages. 13 
Serum samples
Human serum samples were obtained from patients, after the preliminary follow-up, over three consecutive weeks, and the three different samples were screened for the presence of anti-Ad36 antibodies using serum neutralization assay. Blood samples were collected in evacuated silicon-coated tubes containing gel for easier separation between serum and blood clot. After blood coagulation, serum was separated by centrifugation at 100 g, collected, and kept frozen at À80 1C until use. The laboratory evaluations were conducted in a blinded manner. For all the above-mentioned viruses, working stocks were prepared as cellular lysates using RPMI with 2% heatinactivated foetal calf serum. Infectivity of virus stock was determined according to the Reed and Muench method: the reciprocals of the highest viral dilution that caused cytopathic effect to 50% of the cells inoculated was determined as 50% of tissue culture infective dose (TCID 50 ) units per ml.
Viruses and cells

Serum neutralization assay
Serum neutralization assay was used to screen serum samples for anti-Ad36 antibodies. All the samples were heat inactivated at 56 1C for 30 min. Equal volumes (0.5 ml) of viral suspension (containing 1 Â 10 2 TCID 50 ) and media containing serial twofold dilutions of serum (1:4-1:128) were mixed and incubated for 1 h at 37 1C.
A measure of 100 ml per well of the serum/virus mixture were added (in quadruple) on A549 cells monolayers, prepared in 96-well plates (IWAKY, UK). The plates were incubated at 37 1C until the cytopathic effect was evident in the virus control. The virus-infected control containing 100, 10 and 1 TCID 50 (no serum) and the mock-infected control were added in each experimental test. The presence of cytopathic effect with the virus and the absence of cytopathic effect on A549 cells in the presence of the test serum were considered as an indication of effective neutralization of the virus because of the presence of antibodies against the virus tested. A serum titer lower than 1:8 was considered to be non-specific neutralization, whereas a serum titer of X1:8 was considered as positive.
Statistical analysis
Descriptive results of continuous variables are expressed as mean (standard deviation). A preliminary comparison of differences between obese (BMIX30) and non-obese (BMIo30) patients is performed by Student's t-test and w 2 , as suitable in the specific subsets. Differences according to Ad36 seropositivity and gender are assessed as well. Associations are presented as odds ratios (ORs) with 95% confidence intervals (CI). Multiple linear regression analysis is thereafter performed challenging the predictability for the dependent variables, BMI and HOMA in models including Ad36 seropositivity. Two-sided P-value o0.05 was considered as statistically significant. All analyses were performed using SPSS 13.0 for Windows (SPSS, Chicago, IL, USA).
Results
Anthropometric and biochemical characteristics of the subjects and serological status are shown in Table 1 . Ad36 seropositivity has a higher prevalence in men (w 2 : 7.623; P: 0.006); as expected, creatinine, WHR and BP are also higher in men.
With regard to obesity, the obese group vs controls is comparable for age and gender composition. Higher prevalences for Ad36 seropositivity (44/68: 64.7% vs 44/135: Gender By separate assessment, gender differences are present according to Ad36 seropositive status. Age, BMI, fat mass percentage, WHR, insulin, blood pressure and HOMA were significantly greater among women in the Ad36 seropositive group (Table 4) . Differently, in men, for any assessed variable, no significant difference was present according to Ad36 seropositive status; however, there is a trend similar to that observed in women.
Obese vs non-obese Obese Ad36 seropositive patients are older in comparison with obese Ad36 seronegative: this is the only significant difference. In non-obese patients, there are significant differences according to Ad36 seropositivity (Table 5) : nonobese Ad36 seropositive patients are older, with greater BMI, WHR, insulin, HOMA and diastolic BP in comparison with non-obese Ad36 seronegative patients (Table 5) .
Correlations
Ad36 seropositivity is significantly associated, by Spearman's correlation, to BMI, WHR and HOMA (Table 6 ).
Model
By multiple linear regression analysis, HOMA, as dependent variable, is significantly explained by the seven considered variables, which account for 45.1% of variance (Table 7) . However, the only significant predictors to HOMA are triglycerides (Po0.006) and BMI (Po0.0001). BMI, as dependent variable, is significantly explained by the same set of considered variables, which account, together, for 44.5% of variance (Table 7) : the significant operating variables are Ad36 seropositivity (Po0.004), HOMA (Po0.0001) and total cholesterol (Po0.039).
Discussion
According to our results, there is a greater hazard of obesity associated with Ad36 seropositivity; Ad36 seropositive subjects also have an increased hazard of essential hypertension and of greater IR. As expected, obese patients, along with greater BMI, have greater IR, in comparison with the control group. 
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To further test the hypothesis that Ad36 is associated with greater BMI and different insulin sensitivity or lipid levels, we compared all variables, including BMI, lipids and HOMA index of Ad36 positive vs Ad36 negative subjects, within the obese group: the only significant difference was a slightly older age among seropositive obese subjects. The same analysis, repeated within the non-obese group, shows significant differences (Table 5) . BMI, WHR, diastolic blood pressure, insulin and HOMA are all significantly greater among the Ad36 seropositive patients. This group of Ad36 seropositive patients is actually composed mostly of mildly overweight subjects, already with a significant IR and some of them have a slightly 'high-normal' diastolic blood pressure. In this subset, Ad36 seropositive status could be also a hallmark of a clinical-metabolic profile possibly preceding obesity and diabetes in non-obese patients.
By the MLR model, aimed at reaching a synthetic representation of our results, we challenge the predictability of BMI, used as a measurement of the grade of OB, and the predictability of HOMA, used as a measurement of IR. HOMA variance, in our model, is explained significantly only by BMI and triglycerides, and not by Ad36 seropositivity, which Obesity, Ad36 and insulin resistance GM Trovato et al does not plausibly account for IR and the degrees of HOMA. Differently, Ad36 seropositivity is significantly present in the model to BMI and accounts reasonably and significantly for the BMI variance; in this model, a significant concurrent contribution of HOMA is also present. These results suggest that a more direct pathophysiological mechanism on establishment and/or maintaining obesity could be operating, and the hypothesis that this could be related to an earlier Ad36 infection is tenable. Differently, Ad36 seropositivity does not account for different degrees of HOMA: thereafter, any likely evidence of effects on IR is missing.
These results are in agreement with experimental animal models and with the behaviour of human-cultured adipocytes. In these studies, the absence of unfavourable functions of Ad36 infection on insulin sensitivity was reported, even in the presence of adipogenic-associated effects. 15 Overweight and obese patients, without other associated conditions, such as diabetes, show regularly increased circulating levels of insulin and other signs of decreased insulin sensitivity. 20, 21 However, obesity is a complex Obesity, Ad36 and insulin resistance GM Trovato et al condition with many causal contributors, including genetic ones and environmental factors; these last are largely beyond individuals' abilities to choose or control. 22, 23 Scientific and clinical findings have increased our understanding of the importance of diagnosing cardiometabolic risk factors and managing them with lifestyle and pharmacological approaches. [24] [25] [26] Despite the emerging strong evidence that associates certain viruses with obesity, much work is still required to elucidate the mechanisms of weight gain after viral infection. 27 Among the investigated mechanisms, Ad36 infection reduces the secretion of leptin and induces greater lipid accumulation in preadipocytes; 28 moreover, infection of adipocytes with Ad-36 leads to increased production of IL-6, which might contribute to chronic lowgrade inflammation, with a process known to be involved in the development of cardiovascular diseases and type 2 diabetes. 29 The increased prevalence of essential hypertension observed in our study could be conjecturally explained also by the production of inflammatory cytokines, induced by Ad36 infection, relevant for the development of atherosclerosis and diabetes. Obesity is significantly more prevalent in women with earlier Ad36 infection. This fact could be conceivably related to a gender-specific endocrine profile and/or to genetic factors, which entail different effects of the Ad36 infection.
One of the limitations of our study is related to the selected sample of patients. However, we considered that a different sample, including also a third group of diabetic subjects, and the inclusion of patients more severely obese would have been an excessively confusing factor for our study. The aim is to investigate whether a greater adiposity is associated with IR, as widely recognized, and to earlier Ad36 infection, as reported elsewhere. Moreover, we attempt to ascertain whether an insulin-sensitivity-related mechanism is the intermediate and required step between Ad36 infection and greater adiposity: with this goal, introducing patients with diabetes, possibly already treated with drugs effective on IR, would add further confounding factors. This broader approach, certainly appropriate and relevant, will require a larger study population.
Conclusion
A significant association of Ad36 seropositivity with obesity and with essential hypertension in human beings is suggested by our study. Our results do not support that any Ad36 adipogenic adenovirus effect is operating in human obesity through an insulin-resistance-related mechanism. Ad36 seropositive status could be also a hallmark of a clinical-metabolic profile possibly preceding obesity and diabetes in non-obese patients. Obesity, Ad36 and insulin resistance GM Trovato et al
